OOIR: Observatory of International Research

Papers

(The median citation count of Seminars in Hematology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
CAR T-cell therapy comes of age: Introductory editorial for the special issue	61
Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial	59
Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies	54
Clonality in immune aplastic anemia: Mechanisms of immune escape or malignant transformation	48
Clinical applications of circulating tumor DNA in Hodgkin lymphoma	46
Insights from the 12th International Workshop on Waldenstrom's Macroglobulinemia	45
Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones?	44
How to set up a clinical research center in Brazil, as an example of a middle-income country	42
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19	39
Epidemiology and etiology of diffuse large B-cell lymphoma	37
Somatic mutations in “benign” blood diseases	30
Lessons learned from the Eµ-TCL1 mouse model of CLL	27
The role of viruses in HIV-associated lymphomas	26
Immune-driven clonal cell selection at the intersection among cancer, infections, autoimmunity and senescence	22
Antibody and immunotherapy in diffuse large B-cell lymphoma	20
The future of lymphoma diagnosis, prognosis, and treatment monitoring in countries with limited access to pathology services	20
TET2 mutation as prototypic clonal hematopoiesis lesion	19
Intestinal microbiome and myelodysplastic syndromes: Current state of knowledge and perspectives for future	18
Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors	17
Vaccinations in patients with chronic lymphocytic leukemia	17
The molecular map of CLL and Richter's syndrome	16
Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?	16
outside front cover, PMS 8883 metallic AND 4/C	15
Tribute to an editor: Neal S. Young As a Medical Editor and Writer	14
outside front cover, PMS 8883 metallic AND 4/C	14

Cellular and immunotherapies for myelodysplastic syndromes	13
Clonal hematopoiesis	13
At the cusp of a cure in Myeloma: Insights into pathogenesis, modeling and therapeutics	12
outside front cover, PMS 8883 metallic AND 4/C	12
B-cell receptor immunoglobulin stereotypy in chronic lymphocytic leukemia: Key to understanding disease biology and stratifying patients	12
Management of Myelodysplastic Syndrome in Pregnant Patients: Treatment Approaches and Considerations	11
Challenges and opportunities of CAR T-cell therapies for CLL	10
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia	10
The biology of classical Hodgkin lymphoma	10
Aplastic anemia: Quo vadis?	10
Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead	9
Mobilizing CARs: Benefits, drawbacks, and directions for outpatient CAR T-cell therapy	8
The psychiatric and psychological sequelae of vaccine-induced immune thrombotic thrombocytopenia (VITT)	8
The pediatric approach to Hodgkin lymphoma	8
Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana	8
A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS	8
Somatic mutations in acquired pure red cell aplasia	7
Somatic compensation of inherited bone marrow failure	7
Genetics of somatic auto-inflammatory disorders	7
Understanding MDS stem cells: Advances and limitations	7
VEXAS within the spectrum of rheumatologic disease	7
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials	7
outside front cover, PMS 8883 metallic AND 4/C	6
Clinical applications of circulating tumor DNA in central nervous system lymphoma	6
The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty's syndrome	6
Modernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parameters	6
Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom’s Macroglobulinemia	6
Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk disease	6
The crossroads of cancer therapies and clonal hematopoiesis	6
DLBCL arising from indolent lymphomas: How are they different?	6
Measurable residual disease after CAR T-cell therapy	5
Forging international collaboration and alliances to establish the largest transplant center in the north of Vietnam	5
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients	5
Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa	5
miRNA Biology in Chronic Lymphocytic Leukemia	5
License for a CAR T: Examining patient eligibility	5
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients	5
Clonal hematopoiesis in the setting of hematopoietic cell transplantation	5
Infectious complications of chimeric antigen receptor (CAR) T-cell therapies	5
outside front cover, PMS 8883 metallic AND 4/C	5
Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress	5
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria	5
The case for prioritizing malignant hematology services in low- and middle-income countries	4
Updates on the biology of chronic lymphocytic leukemia: introductory editorial	4
Inflammation in myelodysplastic syndrome pathogenesis	4
Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implications	4
Role of the tumor microenvironment in CLL pathogenesis	4
Toward a pathophysiology inspired treatment of VEXAS syndrome	4
outside front cover, PMS 8883 metallic AND 4/C	4
Highlights of the 11th International Workshop on Waldenstrom's Macroglobulinemia: What we learned, and how it will impact scientific discovery and patient care	4

RNA splicing as a therapeutic target in myelodysplastic syndromes	4
Platelet-activating anti-PF4 disorders: An overview	4
Melanoma antigen genes (MAGE); novel functional targets in multiple myeloma	4
Collaborations, colleagues, and friendships: The Hematology Branch and blood disease centers in Asia	4
The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era	4
AML diagnostics in the 21st century: Use of AI	4
Special edition of the Seminars in Hematology series on Global Hematology Care	4
masthead	3
The genomic landscape of acute myeloid leukemia: Redefining classifications, ontogeny, and therapeutic strategies	3
Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome	3
Special issue on circulating tumor DNA: Introductory editorial	3
Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT)	3
outside front cover, PMS 8883 metallic AND 4/C	3
Applications of virus-specific T cell therapies post-BMT	3
Inequalities in access to treatment in Argentina: Differences in management of CLL and multiple myeloma?	3
Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes	3
The Management of older patients with Hodgkin lymphoma: implications of S1826	3
Tuning CAR T-cell therapies for efficacy and reduced toxicity	3
The Road More or Less Traveled- Examining the Role of Consolidative Allogeneic Hematopoietic Stem Cell Transplantation After Chimeric Antigen Receptor T Cell Therapy in B-cell ALL	3